A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
Status:
Completed
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
The study purpose is to evaluate the potential for a pharmacokinetic drug-drug interaction,
safety and tolerability when Narlaprevir, Ritonavir (used as a metabolic inhibitor) and
Tenofovir disoproxil fumarate (part 1) and Narlaprevir, Ritonavir and Raltegravir (part 2)
are administered in combination to healthy volunteers.